Experimental vaccine aims to turn immune system against Hard-to-Treat cancers
NCT ID NCT01147965
First seen Jan 10, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This study tested a cancer vaccine called ETBX-011 in 43 people with advanced colorectal, lung, breast, or prostate cancers that make a protein called CEA. The vaccine uses a modified virus to teach the immune system to find and attack CEA-making cancer cells. The main goals were to check safety and see if the vaccine triggers a strong immune response against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke Cancer Research Institute, Duke University
Durham, North Carolina, 27710, United States
-
Medical Oncology Associates, PS
Spokane, Washington, 99208, United States
Conditions
Explore the condition pages connected to this study.